Given that IDO1 can induce immunosuppressive immune cells, including Treg cells in TME, and anti-VEGF therapy correlates to the increase in IDO1 expression, it is worth exploring whether the addition of IDO1 inhibitors improves the performance of anti-angiogenic drugs against glioma. The gene discussed is IDO1; the disease is central nervous system cancer.